After hours:
Chart Events
Performance Outlook
| Previous Close | 55.70 |
| Open | 55.09 |
| Bid | 56.45 x 900 |
| Ask | 59.16 x 900 |
| Day's Range | 54.33 - 56.71 |
| 52 Week Range | 27.35 - 59.75 |
| Volume | |
| Avg. Volume | 1,402,732 |
| Market Cap | 6.177B |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.84 |
| Earnings Date | May 03, 2023 - May 08, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.00 |
- Business Wire
New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
AUSTIN, Texas, March 22, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to inform adjuvant treatment decisions and monitor for recurrence and therapy response in patients with stages III-IV melanoma. The full study can be found here.
- Business Wire
Natera Announces Commercial Payor Coverage for Signatera™
AUSTIN, Texas, March 02, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring.
- Zacks
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
